Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients
详细信息 查看全文
- 作者：Marta Garcia-Montojo (1)
Virginia De Las Heras (1)
Manuel Bartolome (1)
Rafael Arroyo (1)
Roberto Alvarez-Lafuente (1) (2) - 关键词：HHV ; 6 ; interferon beta ; MxA ; MMP ; 9 ; multiple sclerosis ; TIMP ; 1
- 刊名：Journal of NeuroVirology
- 出版年：2007
- 出版时间：November 2007
- 年：2007
- 卷：13
- 期：6
- 页码：504-512
- 全文大小：325KB
- 参考文献：1. Ahlqvist J, Fotheringham J, Akhyani N, Yaoo K, Fogdell Hahn A, Jacobson (2005). Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. / J NeurVirol 11: 384鈥?94. CrossRef
2. Alvarez-Lafuente R, Mart铆n-Estefan铆a C, De las Heras V, Castrillo C, Cour I, Picazo JJ, Varela de Seijas E, Arroyo R (2002a). Prevalence of herpesvirus DNA in MS patients and healthy blood donnors. / Acta Neurol Scand 105: 95鈥?9. CrossRef
3. Alvarez-Lafuente R, Mart铆n-Estefan铆a C, De las Heras V, Castrillo C, Picazo JJ, Varela E, Arroyo R (2002b). Active human herpesvirus 6 infection in patients with multiple sclerosis. / Arch Neurol 59: 929鈥?33. CrossRef
4. Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, Livrea P, Trojano M (2005). Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. / Mult Scler 11: 441鈥?46. CrossRef
5. Cermelli C, Berti R, Soldan SS, Mayne M, D鈥檃mbrosia JM, Ludwin SK, Jacobson S (2003). High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. / J Infect Dis 187: 1377鈥?387. CrossRef
6. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M, Schad PA, Stewart PM, Nowinski RC, Brown PB, Burmer GC (1995). Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. / Proc Natl Acad Sci USA 92: 7440鈥?444. CrossRef
7. Chapenko S, Millar A, Nora Z, Logina I, Kukaine R, Murovska M. (2003). Correlation between HHV-6 reactivation and multiple sclerosis disease activity. / J Med Virol 69: 111鈥?17. CrossRef
8. Deisenhammer F, Reindl M, Harvey J (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. / Neurology 52: 1239鈥?243.
9. European Study Group on interferon beta-1b in secondary progressive MS (1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. / Lancet 352: 1491鈥?497. CrossRef
10. Gilli F, Bertolotto A, Sala A, Hoffman F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RLP, Leppert D (2004). Neutralizing antibodies against IFN-尾 in multiple sclerosis: antagonization of IFN-尾-mediated supp suppression of MMPs. / Brain 127: 259鈥?68. CrossRef
11. Gilli F, Sala A, Bancote C, Salacone P, Gallo M., Gaia E, Bertolotto A (2002). Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients. / J Immunol Methods 262: 187鈥?90. CrossRef
12. Giovannoni F, Munschauer E 3rd, Deisenhammer F (2002). Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. / J Neurol Neurosurg Psychiatry 73: 465鈥?69. CrossRef
13. Hickey WF, Hsu BL, Kimura H (1991). T-lymphocyte entry into the central nervous system. / J Neurosci Res 28: 254鈥?60. CrossRef
14. Higashikata T, Yamagishi M, Sasaki H, Minatoya K, Ogino H, Ishibashi-Ueda H, Hao H, Nagaya N, Tomoike H, Sakamoto A (2004). Application of real-time RT-PCR to quantifying gene expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human abdominal aortic aneurysm. / Atherosclerosis 177: 353鈥?60. CrossRef
15. Hong J, Tejada-Sim贸n MV, Rivera VM, Zang YCQ, Zhang JZ (2002). Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. / Mult scler 8: 237鈥?42. CrossRef
16. Hymas W, Stevenson J, Taggart EW, Hillyard D (2005). Use of lyophilized standards for the calibration of a newly developed real time PCR assay for human herpes type six (HHV6) variants A and B. / J Virol Methods 143鈥?50.
17. Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Gininger DG, Wong DT, Schmidt BL (2004). Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. / Clin Cancer Res 10: 6460鈥?465. CrossRef
18. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K (1999). Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. / Brain 122: 191鈥?97. CrossRef
19. Lepert D, Lindberg RL, Kappos L, Leib SL (2001). Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. / Brain Res Rev 36: 249鈥?57. CrossRef
20. Medeiros M, Sharma VK, Ding R, Yamaji K, Li B, Muthukumar T, Valderde-Rosas S, Hernandez AM, Mu帽oz R, Suthanthiran M (2003). Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. / J Immunol Methods 279: 135鈥?42. CrossRef
21. Myhr KM, Ross C, Nyland HI, Bendtzen K, Vedeler CA (2000). Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. / Neurology 55: 1569鈥?572.
22. Opdenakker G, Van den Steen PE, Dubos B, Nelissen I, Van Damme J (2001). Gelatinase B functions as regulator and effector in leukocyte biology. / J Leukoc Biol 69: 851鈥?59.
23. Pachner AR, Bertolotto A, Deisenhammer F (2003). Measurement of MxA or protein as a biomarker of IFN尾 bioactivity. / Neurology 61(Suppl 5): S24-S26.
24. Pachner AR, Dail D, Pak E, Narayan K (2005). The importance of measuring IFN-尾 antibodies bioactivity: Monitoring in MS patients and the effect of anti-IFN-尾 antibodies. / J Neuroimmunol 166: 180鈥?88. CrossRef
25. Pachner AR, Narayan K, Price N, Hurd M, Dail D (2003). MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. / Mol Diagn 7: 17鈥?5. CrossRef
26. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O鈥機onnor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group (2002). Evidence of Interferon Dose-response: European North American Comparative Efficacy, University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS. / Neurology 59: 1496鈥?506.
27. Raine CS, Canella B, Duijvestijn AM, Cross AH (1990). Homing to central nervous system vasculature by antigen-specific lymphocytes.II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. / Lab Invest 63: 476鈥?9.
28. Rice G (2001). The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. / Arch Neurol 58: 1297鈥?. CrossRef
29. Ross C, Clemmesen KM, Svenson M (2000). Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. / Ann Neurol 48: 706鈥?12. CrossRef
30. Rudick RA, Simonian NA, Alam JA (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). / Neurology 50: 1266鈥?272.
31. Sorensen PS, Ross C, Clemmesen KM., Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group (2003). Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. / Lancet 362: 1184鈥?191. CrossRef
32. Suhayl DJ (2002). Mechanism of action of interferons and glatiramer acetate in multiple sclerosis. / Neurology 58: S3-S9.
33. Tejada-Simon MV, Zang YCQ, Hong J, Rivera VM, Zhang JZ (2003). Cross-reactivity with myelin basic protein and human-herpesvirus-6 in multiple sclerosis. / Ann Neurol 53: 189鈥?7. CrossRef
34. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996). Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. / Neurology 47: 889鈥?94.
35. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (2005). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. / Neurology 45: 1277鈥?285.
36. Waubant, E., Goodkin, D., Bostrom, A., Bacchetti, P., Hietpas, J., Lindberg, R., Leppert, D (2003). IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. / Neurology 60: 52鈥?7.
37. Yong VW, Krekoski CA, Forsyth P, Bell R, Edwards DR (1998). Matrix metalloproteases and disease of the CNS. / Trends Neurosci 21: 75鈥?0. CrossRef - 作者单位：Marta Garcia-Montojo (1)
Virginia De Las Heras (1)
Manuel Bartolome (1)
Rafael Arroyo (1)
Roberto Alvarez-Lafuente (1) (2)
1. Servicio de Neurolog铆a, Hospital Cl铆nico San Carlos, Madrid, Spain
2. Laboratorio de Investigaci贸n 7a Norte, Hospital Cl铆nico San Carlos, C./ Profesor Mart铆n Lagos s/n., 28040, Madrid, Spain - ISSN：1538-2443
文摘
Viral infections have been appointed as the main component of environmental susceptibility to multiple sclerosis (MS). Interferon beta is an immunomudulatory treatment that is able to modify the natural course of the disease; nonetheless, its mechanism of action in not well established yet. The objectives of the present study were (1) to evaluate the bioavailability of interferon beta through the measurement of the expression of myxovirus resistance protein (MxA), metalloproteinase 9 (MMP-9), and its inhibitor (TIMP-1); (2) to analyze its antiviral efficiency through the measurement of human herpesvirus-6 (HHV-6) prevalence; and (3) to correlate both parameters (bioavailability and antiviral efficiency) with the relapse rate in multiple sclerosis (MS) patients treated with interferon beta. Pairs of blood and serum samples were collected from 54 MS patients during five visits in 1 year: one before the start of the treatment and four during interferon beta treatment. Expression of MxA, MMP-9, and TIMP-1 was analyzed by quatitative real-time polymerase chain reaction (qRT-PCR) and HHV-6 genomes were detected by qPCR. The results showed a correlation between MxA and relapse rate (P = .014). MMP-9/TIMP-1 ratio was increased among the patients with relapses, and decreased among the relapse-free patients, although differences were not statistically significant. Furthermore, our results suggest a possible role for HHV-6 in MS, because 42.8% of patients with viral reactivations experienced at least one relapse versus 22.5% of patients without viral reactivations. Lastly, regarding the antiviral effectiveness of the interferon beta, the HHV-6 prevalence decreased from 58% to 36% in PBMCs and from 18.5% to 12.2% in sera; furthermore, a good correlation with the bioavailability of interferon beta was found, because patients with a decrease in HHV-6 prevalence had higher levels of MxA (P = .046, at the third month).